ZVSA

ZyVersa Therapeutics, Inc.

OTC · Pharmaceutical Preparations · Inc. DE · CIK 0001859007
$0.1749 -0.06%
Vol
Inst. Holders2 funds
Inst. Value$26.7K
Inst. Activity0 buys / 1 sells
SEC Reports1
Exchange OTC·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001859007·Prev Close $0.1750

Recent Activity

Mar 5, 2026 SEC
ZyVersa Therapeutics raised $1 million through a private placement of convertible promissory notes and warrants to accre
8-K — Impact 4/10
Inst.
UBS Group AG — EXIT
0 shares ($0.00)
Inst.
UBS Group AG — ADD
39,280 shares ($26.6K)
May 13, 2026 earnings_calendar
ZVSA Q1 2026 Earnings Scheduled — 2026-05-13

Analyst Ratings

Historical distribution88% buy · 8 analysts · last covering-analyst action Mar 2024
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Mar 26, 2024 HC Wainwright & Co. REITERATE Buy → Buy
Mar 12, 2024 HC Wainwright & Co. MAINTAIN Buy → Buy
Feb 29, 2024 HC Wainwright & Co. REITERATE Buy → Buy

Top Institutional Holders

FundValueMove
UBS Group AG$26.6KEXIT
BANK OF AMERICA CORP$90.00
2 institutional holders with $26.7K total value (39,412 shares) as of 2025-Q2. Top holders: UBS, BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q2

#FundSharesValue% of TrackedLast Move
1UBS Group AG39,280$26.6K99.7%EXIT -100.0%
2BANK OF AMERICA CORP /DE/132$90.000.3%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
UBS Group AGEXIT39,2800-100.0%$0.002025-Q3
UBS Group AGADD28,32739,280+38.7%$26.6K2025-Q2
UBS Group AGDOUBLED4,18728,327+576.5%$17.8K2025-Q1
RENAISSANCE TECHNOLOGIES LLCEXIT12,9610-100.0%$0.002025-Q1
RENAISSANCE TECHNOLOGIES LLCNEW12,961$13.7K2024-Q4
UBS Group AGDOUBLED4334,187+867.0%$4.4K2024-Q4

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Mar 2024): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
2025-03-31
$0.00 $0.00 $0.00 $0.0B
Current FY
2024-12-31
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Mar 26, 2024 HC Wainwright & Co. REITERATE Buy Buy
Mar 12, 2024 HC Wainwright & Co. MAINTAIN Buy Buy
Feb 29, 2024 HC Wainwright & Co. REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Mar 1, 20252510088%
Feb 1, 20252510088%
Jan 1, 20252510088%
Dec 1, 20242510088%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 13, 2026
earnings_calendar
ZVSA Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
ZVSA Q1 2026 Earnings Scheduled — 2026-05-11
Mar 25, 2026
earnings_calendar
ZVSA Q4 2025 Earnings After Market Close — 2026-03-25